Across TCGA pan-cancer cohorts, LSM6 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LSM6 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher LSM6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LSM6 expression acts as an unfavorable survival marker.
LUSC and SKCM are the cancer types where LSM6 Mutation most reproducibly stratifies survival.